Prevention of vascular-allograft rejection by protecting the endothelial glycocalyx with immunosuppressive polymers.
Erika M J SirenHaiming D LuoFranklin TamAshani MontgomeryWinnie EnnsHaisle MoonLyann SimKevin ReyQiunong GuanJiao-Jing WangChristine M WardellMahdis MonajemiMajid MojibianMegan K LevingsZheng Jenny ZhangCaigan DuStephen G WithersJonathan C ChoyJayachandran N KizhakkedathuPublished in: Nature biomedical engineering (2021)
Systemic immunosuppression for the mitigation of immune rejection after organ transplantation causes adverse side effects and constrains the long-term benefits of the transplanted graft. Here we show that protecting the endothelial glycocalyx in vascular allografts via the enzymatic ligation of immunosuppressive glycopolymers under cold-storage conditions attenuates the acute and chronic rejection of the grafts after transplantation in the absence of systemic immunosuppression. In syngeneic and allogeneic mice that received kidney transplants, the steric and immunosuppressive properties of the ligated polymers largely protected the transplanted grafts from ischaemic reperfusion injury, and from immune-cell adhesion and thereby immunocytotoxicity. Polymer-mediated shielding of the endothelial glycocalyx following organ procurement should be compatible with clinical procedures for transplant preservation and perfusion, and may reduce the damage and rejection of transplanted organs after surgery.
Keyphrases
- cell adhesion
- endothelial cells
- drug induced
- stem cell transplantation
- bone marrow
- acute myocardial infarction
- type diabetes
- cell therapy
- climate change
- heart failure
- magnetic resonance imaging
- nitric oxide
- metabolic syndrome
- magnetic resonance
- intensive care unit
- high fat diet induced
- adipose tissue
- coronary artery disease
- low dose
- cerebral ischemia
- acute respiratory distress syndrome
- hematopoietic stem cell
- mesenchymal stem cells
- aortic dissection
- acute ischemic stroke
- high dose
- brain injury
- atrial fibrillation
- contrast enhanced
- adverse drug
- wild type